4-aminopyridine for Skin Wound Healing

NCT ID: NCT06333171

Last Updated: 2025-09-03

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-30
• Study Completion Date: 2028-03-31

Brief Summary

Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults.

The purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing.

The investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.

Detailed Description

Worldwide, hundreds of millions of patients suffer from chronic non-healing wounds. In addition, most people will experience acute wounding at some point in their life. There is a need to develop agents to treat chronic and acute wounds. This need has intensified with the aging of the population, the rising incidence of diabetes and obesity, and the increasing number of patients undergoing treatment with medications that adversely affect wound healing.

Through experiments performed on animals with 4-aminopyridine, (currently marketed by Acorda Healthcare, Inc. in slow-release form as AMPYRA®, and available in generic form proposed for use in this study), the investigators found striking effects on wounds in the standard rodent model used in the literature. In these experiments, animals with wounds held open with stents, healed faster with mass-adjusted human doses of 4-AP. All relevant markers of tissue regeneration were augmented with 4-AP treatment. These injuries are considered standard models, used for decades that correlate to those encountered in the human patients.

The investigators found that:

1. 4-AP administration over just 21 days led to a large augmentation of wound healing at time points as early as three days post injury.

2. 4-AP treatment was associated with no adverse events in animals at the doses used consistent with our previous applications.

3. Numerous measures of wound healing at the cellular level showed quantifiable improvement with treatment at the tissue level.

4-AP is used in some of the most fragile of neurologically-ailing patients and is currently a mainline treatment in the setting of multiple sclerosis. Multiple sclerosis patients suffer a demyelinating disorder that causes the stripping of the myelin sheath from around neurons in the peripheral and central nervous system. The myelin covering allows for normal conduction of impulses and, without such covering, impulses are small, impaired, impeded, and ineffective. The recognition that crush injuries to nerves do not simply sever the axonal fibers but also demyelinate some population of nerve cells has led to the idea to study the treatment of peripheral nerve traumatic injuries in humans using 4-AP and this continues to be the subject of some of the investigator's other translational work

There is extant literature demonstrating the positive effects of electrical stimulation in wound healing. Electrical stimulation of wounds has been shown to be effective in accelerating wound repair for diabetic foot ulcers and other chronic skin ulcers. Direct electrical stimulation of the skin is labor intensive, while 4-AP is more easily administered as an oral therapy. Thus, the recognition that re-innervation may improve healing in the wound bed - and that 4-AP has a differential, clinically relevant effect on nerves and wounds naturally leads to this application.

Conditions

Wounds; Wound of Skin; Wound Heal; Wounds and Injuries

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Group A: 4-aminopyridine

dalfampridine (generic) 10 mg capsule po every 12 hours

Group Type: ACTIVE_COMPARATOR

4-Aminopyridine

Intervention Type: DRUG

Active study drug

Group B: Placebo

Placebo-1 capsule po every 12 hours

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo comparator

Interventions

4-Aminopyridine

Active study drug

Intervention Type: DRUG

Placebo

Placebo comparator

Intervention Type: OTHER

Other Intervention Names

4AP, dalfampridine

Eligibility Criteria

Inclusion Criteria

• Otherwise healthy adult patients without skin conditions effecting the skin of the axilla or upper inner arm.
• Cognitive ability to evaluate wound healing, report sensory and motor deficit during examination.
• Eligible for standard of care plan for wound closure by secondary intention (normal healing without intervention).
• Adults subject aged 18-70
• Ability to give written informed consent.
• Capable of safely coming in for follow up visits on all scheduled appointments.

Exclusion Criteria

• History of multiple sclerosis, stroke or any other diagnosed neurological disorder
• History of hypersensitivity to AMPYRA® or 4-aminopyridine
• Current use of aminopyridine medications, including other compounded 4-AP
• Suspected renal impairment based on the Choyke questionnaire.
• History of difficult compliance with timely follow up
• Patients outside the age range
• Unable to provide informed consent.
• Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).
• Patients with a concomitant traumatic brain injury.
• Patients unable to communicate.
• Patients unwilling to complete the study requirements.
• Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.
• Pregnancy, breastfeeding or incarcerated individuals.
• Non-English speaking
• Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

John Elfar

OTHER

Sponsor Role: lead

Responsible Party

John Elfar

Tenured Professor, Chairman, Department of Orthopaedic Surgery

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

John Elfar, MD

Role: PRINCIPAL_INVESTIGATOR

University of Arizona

Locations

University of Arizona

Tucson, Arizona, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Andrea Horne

Role: CONTACT

ahh@arizona.edu

520-626-6456

Facility Contacts

Andrea Horne

Role: primary

ahh@arizona.edu

520-626-6456

Other Identifiers

00003872

Identifier Type: -

Identifier Source: org_study_id